Agalsidase alfa – a preparation for enzyme replacement therapy in Anderson–Fabry disease

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.11, Iss.6, 2002-06, pp. : 851-858

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Anderson-Fabry Disease in Children

Current Pharmaceutical Design, Vol. 19, Iss. 33, 2013-10 ,pp. : 6037-6045

Bentham Science Publishers

Access to resources Recommend Favorite

Enzyme Replacement Therapy in Orphan and Ultra-Orphan Diseases: The Limitations of Standard Economic Metrics as Exemplified by Fabry-Anderson Disease

By Moore David F.

PharmacoEconomics, Vol. 25, Iss. 3, 2007-01 ,pp. : 201-208

Adis International

Access to resources Recommend Favorite

Enzyme Replacement Therapy in Patients with Fabry's Disease

By Tsuboi K

The Journal of International Medical Research, Vol. 35, Iss. 4, 2007-07 ,pp. : 574-581

Field House Publishing

Access to resources Recommend Favorite

Fabry disease: recent advances in enzyme replacement therapy

By Germain Dominique P

Expert Opinion on Investigational Drugs, Vol. 11, Iss. 10, 2002-10 ,pp. : 1467-1476

Informa Healthcare

Access to resources Recommend Favorite

Anderson-Fabry Disease: A Multiorgan Disease

Current Pharmaceutical Design, Vol. 19, Iss. 33, 2013-10 ,pp. : 5974-5996

Bentham Science Publishers

Access to resources Recommend Favorite